Balyasny Asset Management
FDMT icon

Balyasny Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Balyasny Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,044
Closed -$298K – 2917
2022
Q3 		$298K Buy
+37,044
New +$336K ﹤0.01% 2198

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Balyasny Asset Management's FDMT Position: Q4 2022 in Review

Balyasny Asset Management sold out of 4D Molecular Therapeutics (FDMT) in Q4 2022, closing a stake of 37,044 shares — an estimated $298K sold.

Balyasny Asset Management first reported a position in FDMT in Q3 2022 and held it in 1 quarter. The position peaked at $298K in Q3 2022. 96 funds tracked by Wall St. Rank hold FDMT as of Q4 2022.

  • Balyasny Asset Management reported no remaining 4D Molecular Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 37,044 4D Molecular Therapeutics shares in Q4 2022, an estimated $298K.
  • Balyasny Asset Management first reported a position in 4D Molecular Therapeutics in Q3 2022 and held it in 1 quarter.
  • Balyasny Asset Management's 4D Molecular Therapeutics position peaked at $298K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.